Organisation paid for research Program year 2025 Source: CMS Open Payments

DaVinci Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$1,414,972

133 payments

Through program year 2025, DaVinci Research, LLC is reported as receiving $1,414,972 in research payments, across 133 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$47,407	6
2024	Research	$27,740	9
2023	Research	$97,139	18
2022	Research	$154,166	22
2021	Research	$567,257	44
2020	Research	$521,262	34

Breakdown

Who paid Research payments · program years 2020–2025

Aerin Medical Inc. $622,696 44 payments
OptiNose US, Inc. $587,916 58 payments
AstraZeneca Pharmaceuticals LP $146,531 12 payments
Smith+Nephew, Inc. $57,828 19 payments

Studies the money was for Research payments · program years 2020–2025

A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps. OPN-FLU-CS-3205. $356,523 29 payments
CTP 1004 - Rhintrac $233,911 11 payments
A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis Without the Presence of Nasal Polyps. OPN-FLU-CS-3206. $175,560 13 payments
Tp900 Aerway $130,762 4 payments
A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT $100,759 7 payments
Tp1004 Rhintrac $76,079 2 payments
CTP 1056 - Relief $70,049 9 payments
OTTER pivotal study $57,256 18 payments
A 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 g Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. OPN-FLU-NP-3103 $52,743 15 payments
CTP 900 - Aerway $43,861 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.